Phlebodia is applied across domains where additional symptomatic support is needed, often used during phases when symptoms become more noticeable. This treatment is considered relevant when supportive symptom management is appropriate for conditions involving episodic or fluctuating manifestations.

This support is commonly used across conditions presenting with acute episodes, including piles (haemorrhoids) and for managing symptoms related to chronic venous insufficiency. The therapeutic benefit provides support that helps ease the overall symptom burden.

The medication addresses symptom clusters that may become intense or disruptive, such as a sensation of heavy legs, pain, early morning restless legs, and night cramps. This makes it helpful in situations requiring additional symptomatic assistance when symptoms create noticeable functional strain.

“This assistance supports general well-being during symptomatic phases and may help patients cope more steadily with symptom fluctuations.”

Quick Fact: May assist with managing Symptoms related to physical discomfort (such as heavy legs and night cramps).

Eligibility scope

Scope	Regulatory Statement
Populations for whom use is allowed:	Use is established for the adult population (18 years and older) for the approved indications.
Populations for whom use is not recommended:	Women who are breastfeeding (lactation). Pregnant women, unless use is considered clearly necessary.
Populations for whom use is contraindicated:	Patients with documented hypersensitivity to the active substance, diosmin, or any of the product's excipients. Patients allergic to the coloring agent Cochineal Red A (E 124).
Age-related eligibility rules:	The safety and efficacy have not yet been established for children and adolescents aged less than 18 years.
Condition-specific eligibility rules:	No explicit restriction is documented for patients with renal impairment or hepatic impairment in the available regulatory sections.
Pregnancy and lactation eligibility status:	Not recommended during lactation due to the absence of data on excretion in human milk. Use in pregnancy is advised to be avoided as a precautionary measure.
Eligibility-related restrictions:	For acute hemorrhoidal attacks, administration does not substitute specific treatment for other anal diseases and should be of short duration.

---

Eligibility Classifications (High-Level)

Classification	Details
Eligibility severity classification:	Absolute Contraindication (Hypersensitivity); Not Recommended (Lactation/Pediatric Population); Conditional Use/Avoided (Pregnancy); Established Use (Adult Population).
Eligibility-context constraints:	Constraints are defined by hypersensitivity, age-related data insufficiency (under 18), and physiological states (pregnancy/lactation).

---

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in patients with a known hypersensitivity to diosmin or the excipient Cochineal Red A (E 124).
• The safety and efficacy have not yet been established for children and adolescents under 18, making use in this population not recommended.
• Use is not recommended during lactation due to the absence of data regarding passage into breast milk.

Connection to the overall eligibility profile: Regulatory documents define use by establishing absolute contraindications based on known allergic risk and formally classifying populations where data is insufficient, such as in children and breastfeeding women, making use not recommended or conditional in those groups.

Interactions with other medicines and products for Phlebodia

The official regulatory profile for Phlebodia, whose sole active ingredient is diosmin, is defined by the findings documented in authoritative government sources regarding its co-administration with other medicinal products and substances. The Summary of Product Characteristics (SmPC), as reviewed by national health authorities, establishes the formal interaction status.

The official regulatory documentation for Phlebodia explicitly states that no clinically relevant drug interaction has been reported to date with diosmin. This translates to the lack of documented constraints based on co-administration risk.

Official Interaction Profile Structure

Interaction Category	Status based on Regulatory Documents
Contraindicated Combinations	None are explicitly listed in the regulatory label due to interaction risk.
Specific Interacting Medicines	None are listed as requiring dose adjustment or co-administration restriction.
Metabolic/Transporter Interactions	No clinically relevant pharmacokinetic or pharmacodynamic interactions have been officially reported.
Timing/Separation Rules	None are documented; no mandatory administration timing rules are imposed.
Food, Alcohol, or Supplements	Officially designated as "Not applicable" in the product information.

This absence of documented constraints forms the official interaction profile of the medication. The clear regulatory finding structures the official interaction map, indicating that restrictions based on drug-drug, drug-food, or drug-substance mechanisms have not been established as clinically significant by health authorities.

Phlebodia's action is governed by a multi-faceted mechanism targeting the venous and microvascular systems, defining its pharmacodynamic action. The active ingredient, diosmin, modulates three core biological domains.

Venous Tone Modulation and Hemodynamics

The drug acts on the neuro-effector junction of the venous wall, enhancing the smooth muscle's contractile response to endogenous vasoconstrictors like norepinephrine (NE). This mechanism is primarily focused on modulating the noradrenergic pathway to promote a sustained increase in venous tone. The physiological result is a decrease in venous capacitance (pooling), which results in a reduction of localized venous pressure and mitigates the physiological state of venous stasis.

Stabilizing Capillary Walls and Anti-Permeability Action

Diosmin exerts a vasculoprotective effect by stabilizing the structure of the capillary endothelium and its outer layer, the glycocalyx. This targeted action increases the capillary resistance and decreases the walls' hyperpermeability, limiting the abnormal leakage of fluid and plasma proteins from the microcirculation into the surrounding tissue. This physiological action opposes the extravasation of fluid that underlies tissue fluid accumulation.

Modulating the Inflammatory Cascade

The molecule demonstrates an inhibitory effect on key enzymes within the inflammatory cascade, notably 5-Lipoxygenase (5-LOX), thereby reducing the localized production of pro-inflammatory mediators such as leukotrienes. This biochemical dampening limits the inflammatory response within the vascular bed, leading to a dampening of local pro-inflammatory signals. The physiological consequences include modulation of microcirculation and reduction of fluid extravasation.

How to Use Phlebodia: Official Administration Guidelines

Phlebodia is a medication taken orally as a film-coated tablet containing 600 mg of diosmin. The way the medicine is used, including the daily dose and the timing of administration, is structured by the specific condition being addressed.

Official Dosing Regimens

Indication	Daily Dose (Diosmin 600 mg)	Timing of Administration	Duration Pattern
Chronic Venous Insufficiency (CVI)	One tablet (600 mg)	Taken once daily in the morning before breakfast	Duration is prescriber-dependent
Acute Hemorrhoidal Attacks	Two to three tablets (1200 mg to 1800 mg)	Divided into doses taken during meals	Treatment must be of short duration

General Administration Instructions

The tablet should be swallowed whole with a glass of water, and should not be crushed or broken. If a dose is missed, guidelines instruct the user to continue treatment at the same prescribed dosages, without attempting to take a double dose to compensate.

There is no established safety or efficacy data for the use of Phlebodia in children and adolescents under 18 years of age. The official administration framework ensures the medicine is used consistently with the regimen and timing defined for this medication.

Research evidence / Overview of Studies for Phlebodia

Evidence for Use in Chronic Venous Insufficiency (CVI) Symptoms

The research landscape includes studies that have explored the compound Diosmin in the context of conditions characterized by fluctuating or episodic manifestations of Chronic Venous Insufficiency (CVI), where outcomes related to physical discomfort like heavy legs, pain, and swelling (edema) are present. Studies primarily include short- to intermediate-term randomized controlled trials ( RCTs) that evaluated Diosmin against inactive controls or observed changes over a set period. Researchers focused on outcomes related to physical discomfort and daily functioning, using patient-reported scores for pain and validated questionnaires to assess changes in quality of life ( QoL). Findings include documentation of changes measured in subjective reports of leg heaviness and pain among the studied populations, and data showing patterns related to measured shifts in leg circumference or volume in some observed populations.

Evidence for Use in Acute Hemorrhoidal Attacks

For conditions associated with acute or disruptive episodes, such as hemorrhoidal attacks, research has included short-term randomized controlled trials focused on observation during an acute symptomatic flare-up. These studies were conducted during periods of increased symptom activity. Research explored outcomes describing episodic changes, particularly the severity and duration of acute symptoms such as pain, bleeding, and localized swelling. Some research describes patterns related to a measured difference in the time taken for symptom evolution in the observed group when compared to control groups, providing context on how symptoms evolved in the observed populations during the specific episode.

What is Still Uncertain about Phlebodia Research

Long-term effects are not fully established across the entire research record. The majority of published research provides insight into short-term changes, with follow-up durations typically limited to intermediate periods of up to six months. Data are still emerging regarding the sustained effects of treatment or patterns of symptom relief over a period of one year or more. Studies providing direct comparative evidence against all other available treatment classes are limited, and research exploring the compound alongside these classes is not extensive. Data for certain special populations, such as children or pregnant individuals, remain insufficient.

Key Studies & References

1. Efficacy of a Low-Dose Diosmin Therapy on Improving Symptoms and Quality of Life in Patients with Chronic Venous Disease: Randomized, Double-Blind, Placebo-Controlled Trial

Common questions about Phlebodia (FAQ)

---

Q: How long does it usually take to feel a difference after starting Phlebodia?

A: Studies that have examined the active ingredient, diosmin, generally track changes over short- to intermediate-term periods, such as up to six months. Official documents state that the substance has an elimination half-life of approximately 11 hours in the body. Since individual responses vary and the time to first effect is not specified, the exact onset time is not defined in the regulatory information.

---

Q: Is Phlebodia safe for long-term use?

A: The research evidence for the active ingredient indicates that the long-term effects are not fully established across the entire clinical record. The majority of published studies provide insight into short-term changes, with follow-up typically limited to intermediate periods of up to six months. Regulatory documents do not contain long-term safety data beyond these trial periods.

---

Q: Have there been any recent large-scale studies on Phlebodia's effects?

A: Regulatory overviews note that research evidence includes randomized controlled trials that have explored the drug’s action. However, comprehensive, large-scale data exploring the sustained effects of treatment over very long periods is described as limited in the available research.

---

Q: Is there a maximum time someone can use Phlebodia?

A: Official instructions for acute hemorrhoidal attacks specify that treatment must be of short duration. For chronic venous insufficiency, the appropriate length of use is not defined by a maximum time and is determined by the healthcare provider.

---

Q: Is Phlebodia approved by the FDA or a similar major regulatory body?

A: The regulatory status of the active ingredient, diosmin, varies globally. For example, in the United States, it is distributed as a dietary supplement and is not approved as a prescription drug. Conversely, in several European countries, it is available as a registered medicinal product.

---

Q: Can Phlebodia be purchased without a prescription in some countries?

A: Yes, the classification of this medicine varies internationally. The product may be sold as either an over-the-counter (OTC) product or a prescription-only drug, depending on the national health authority and the country where it is marketed.

---

Q: Is Phlebodia considered a preventative measure for vein problems?

A: Regulatory documents indicate that the medicine is used for the management of established signs and symptoms associated with conditions like chronic venous insufficiency. Its approved indications relate to the treatment of existing symptoms rather than acting as a primary preventative measure for vein problems.

---

Q: Can men use Phlebodia, or is it only for women with circulatory issues?

A: Official eligibility documents establish use for the general adult population (18 years and older), which includes men. The only constraints specifically noted in the regulatory documents are related to age and the physiological states of women, such as pregnancy and lactation.

---

Q: Are there different brand names that contain the same active ingredient as Phlebodia?

A: Yes, the active ingredient, diosmin, is available internationally under various other brand names. The specific product name can differ depending on the country and the marketing authorization holder.

---

Q: What is the difference between Phlebodia and micronized purified flavonoid fraction (MPFF)?

A: Phlebodia’s active composition is defined by its sole ingredient, diosmin. Micronized Purified Flavonoid Fraction (MPFF) is a specific formulation that typically contains 90% diosmin combined with 10% other flavonoids, such as hesperidin.

---

Q: Does Phlebodia contain lactose, gluten, or common allergens?

A: Official excipient lists generally do not include common allergens like lactose or gluten in the formulation. However, regulatory documents note that the product contains the coloring agent Cochineal Red A (E 124), and this agent is noted in the label as an excipient associated with known hypersensitivity risk.

---

Q: What should be done if an overdose of Phlebodia is suspected?

A: Official documentation notes that experience with overdose is limited, and the most frequently reported effects were generally mild gastrointestinal or skin events. Regulatory guidance for overdose suggests seeking medical attention immediately and treating the reported clinical symptoms.

How to Store and Dispose of Phlebodia

Official regulatory documents define strict conditions for the storage and disposal of Phlebodia 600 mg tablets to maintain stability and ensure environmental safety.

---

Storage Requirements

• Temperature: The medicine must not be stored above 30 C.
• Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.
• Stability: The product has a labeled shelf life of 5 years; do not use the medicine after the expiry date.
• Packaging: The product should be kept in its original PVC/Aluminium blister packaging.

---

Disposal Instructions

Official instructions require that any unused or expired Phlebodia be disposed of properly. Do not throw away any medicines via wastewater or household waste. Disposal must be completed in accordance with local requirements, and patients are advised to consult a pharmacist for guidance on proper discarding procedures.